GILEAD SCIENCES, INC.
GILDNasdaqGSDrug Manufacturers - General • Healthcare
Comprehensive AI Analysis
Strategic AI Analysis for GILD
Checking whether the approved providers contain enough current financial data for a reliable report.
Summary
Source-linked company research for GILD
Factor Scorecard
Mechanical 0-100 composites from the displayed inputs. Bands and colours are numerical aids, not security ratings or investment actions.
Latest results at a glance
Insights from the latest company results and reports · filed 4 Aug 2026
Q2 Revenue Growth Driven by HIV
Total revenue for the quarter ended June 30, 2026, was $7.80 billion, representing a 10.18% increase from the same period in 2025.
Acquired IPR&D Drives Net Loss
GAAP diluted loss per share was $(8.45) in the second quarter of 2026, compared to $1.56 in the same period of 2025. The decline was primarily driven by a $(9.08) per share impact from acquired in-process research and development expenses related to recent acquisitions.
HIV Portfolio Strengthens Revenue Base
Descovy revenue reached $2.56 billion for the fiscal year ended December 31, 2025, up 34.5% year-over-year. Biktarvy generated $11.47 billion in revenue for the same period, representing 38.9% of consolidated revenue.
Cash Position Reduced by Acquisitions
As of June 30, 2026, Gilead held $3.2 billion in cash, cash equivalents, and marketable debt securities, down from $10.6 billion at the end of 2025.
Product Gross Margin Remains Stable
Product gross margin was 79.3% in the second quarter of 2026, compared to 78.7% in the same period of 2025. Non-GAAP product gross margin remained flat at 86.9% year-over-year.
Price Chart
NASDAQ:GILD via TradingView
Loading TradingView chart...
Overview
Quarterly income statement data isn't available for this company.
No Data
No annual financial data available.
Financial Fundamentals
Growth, quality, valuation, cash generation, and balance-sheet strength.
Growth
TTM revenue plus current, long-term, forward, and accelerating top-line trends.
Earnings
Trailing EPS, current EPS growth, long-term compounding, surprise, and forward expectations.
Profitability
TTM margin and return metrics that reflect pricing power and business quality.
Cash Flow
TTM free cash flow, growth, margin, and operating-cash conversion quality.
Valuation
Metrics ranked by issuer type, financial state, and input quality.
Price / Sales
P/S is the primary available lens because earnings are not positive while revenue remains measurable.
Financial Health
Latest-quarter liquidity and leverage checks plus TTM interest coverage.
Shareholder Signals
Capital returns and dilution checks sourced from statements and insider filings.
Peer Comparison
| Ticker | Price | Mkt Cap | EV/EBITDA | Fwd P/E | Rev Growth | Gross Margin | FCF Yield |
|---|---|---|---|---|---|---|---|
GILDGILEAD SCIENCES, INC. | $145.68 | $180.6B | — | — | +5.5% | 79.6% | 7.2% |
Company Profile
About the Company
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Next Earnings Date
Oct 29, 2026
Loading latest news...